February 10, 2017
Authored and Edited by Adriana L. Burgy; Leslie A. McDonell; Amanda K. Murphy, Ph.D.
Patent eligibility is a balancing act; the Supreme Court explained in Mayo that “too broad an interpretation of this exclusionary principle could eviscerate patent law. For all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ides.” In an era of subject matter eligibility uncertainty, the on-going question is: How do you deal with 101 rejections and, in particular, for diagnostic inventions in the life sciences space? In a series of posts, we will explore different strategies to answer that question.
Before starting, it’s useful to keep up with the latest court decisions. The USPTO keeps a summary of patent eligibility cases, a link to which can be found here. The link is to the USPTO’s “Subject Matter Eligibility” page, which includes useful examination guidance, examples, materials, and events.
One strategy, a common prosecution tool, is to keep a continuation application pending. With the continually-developing case law on subject matter eligibility, it may be helpful to keep a continuation application on file while Congress and/or the courts continue to address the question of what is patentable subject matter. While this strategy does not solve the problem of obtaining allowable claims, it provides applicants with the ability to obtain claim coverage now based on current standards, while preserving the opportunity to obtain broader coverage once the state of the law has further developed.
While the Supreme Court and Federal Circuit decisions on patent eligibility for diagnostic life sciences claims seem rather dim, applicants can find hope in the instances in which life sciences claims are held to contain eligible subject matter. As former Chief Judge Giles Rich proclaimed, “The name of the game is the claim.” Stay tuned for Part II in which we will look at claiming strategies.
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.